EIS-12656

EIS-12656 is a first-in-class, orally bioavailable small molecule that acts as an allosteric inhibitor of the chromatin helicase ALC1 (also known as CHD1L). Developed by Eisbach Bio, this agent selectively targets and inhibits ALC1 activity in tumor cells, thereby preventing ALC1/poly(ADP-ribose) polymerase (PARP)-mediated repair of DNA breaks. By suppressing cancer-relevant genome reorganization induced by DNA damage, EIS-12656 leads to chromatin trapping and cancer cell death. The drug is designed for the treatment of advanced solid tumors—particularly those deficient in homologous recombination repair pathways or resistant to PARP inhibitors. Preclinical studies have demonstrated substantial tumor growth inhibition, blood-brain barrier penetration, and a favorable safety profile. Clinical development is ongoing with phase 1/2 trials evaluating its use both as monotherapy and in combination with standard-of-care therapies[2][5][7][9].

Other names

ALC1 inhibitor EIS-12656ALC-1 inhibitor EIS-12656ALC 1 inhibitor EIS-12656